15/11/2024  21:08:44 Diferencia +0.23 Volumen Bid22:00:16 Ask22:00:16 Capitalización de mecado Dividendo A. P/E Ratio
12.18EUR +1.88% 7,633
Volumen de negocios: 89,651.14
12.12Volumen de oferta: 495 12.27Tamaño/ Volumen/ Formato de Ask: 488 14.55 mil millonesEUR - -

Descripción de negocio

Viatris Inc. is a new kind of healthcare company, empowering people worldwide to live healthier at every stage of life. We provide access to medicines, advance sustainable operations, develop innovative solutions and leverage our collective expertise to connect more people to more products and services through our one-of-a-kind Global Healthcare Gateway™. Formed in November 2020 through the combination of Mylan and Pfizer's Upjohn business, Viatris brings together scientific, manufacturing and distribution expertise with proven regulatory, medical and commercial capabilities to deliver high-quality medicines to patients in more than 165 countries and territories. Viatris' portfolio comprises more than 1,400 approved molecules across a wide range of therapeutic areas, spanning both non-communicable and infectious diseases, including globally recognized brands, complex generic and branded medicines, a growing portfolio of biosimilars and a variety of over-the-counter consumer products. With a global workforce of approximately 45,000, Viatris is headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India.
 

Consejo de gestión & Consejo de supervisión

CEO
Scott A. Smith
Consejo de gestión
Sanjeev Narula, Rajiv Malik, Robert J. Coury
Consejo de supervisión
Robert J. Coury, W. Don Cornwell, JoEllen Lyons Dillon, Elisha W. Finney, Leo Groothuis, Melina Higgins, James Kilts, Harry A. Korman, Rajiv Malik, Richard A. Mark, Mark W. Parrish, Scott A. Smith, Pauline van der Meer Mohr
 

Datos de la empresa

Nombre: Viatris Inc.
Dirección: 1000 Mylan Boulevard, Canonsburg,Pennsylvania, 15317, USA
Teléfono: +1-724-514-1800
Fax: -
E-mail: -
Internet: https://www.viatris.com/en
Industria: Healthcare
Sector: Pharmaceutical Industry
Subsector: Pharmaceuticals
Fin del año financiero: 31/12
Acciones de libre circulación: -
Fecha de OPI: 16/11/2020

Relación con inversores

Nombre: Bill Szablewski
IR teléfono: +1-412-707-2866
IR-fax: -
IR e-mail: InvestorRelations@viatris.com

Calendario de la empresa

CW 47 | 22/11/2024 Record Date
CW 47 | 22/11/2024 Ex-Dividend
CW 49 | 06/12/2024 General Shareholder Meeting
CW 50 | 13/12/2024 Dividend Payment
 

Accionistas mayoritarios

Otros
 
55.73%
Vanguard Group Inc
 
11.94%
BlackRock Inc.
 
7.75%
Davis Selected Advisers, LP
 
5.26%
State Street Corporation
 
5.20%
Price T Rowe Associates Inc Md
 
4.15%
Invesco Ltd.
 
2.53%
Geode Capital Management, LLC
 
2.30%
Pacer Advisors Inc
 
1.75%
Otros
 
3.39%